Skip to main content
Log in

The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence declinein the United States

  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Objectives: Trends in first-time and later PSA procedure rates are ascertained using longitudinal data from a population-based cohort. These trends are compared to trends in prostate cancer incidence to determine the role of PSA in the recent decline in prostate cancer incidence.

Methods: Medicare data were linked with tumor registry data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. A 5 percent random sample (n=39985) of Medicare beneficiaries from the SEER areas without a previous diagnosis of prostate cancer as of January 1, 1988 was followed through 1994. Trends in first-time PSA use were distinguished from those of second or later for men without diagnosed prostate cancer.

Results: Trends in the rate of first-time PSA procedures track closely with trends in prostate cancer incidence rates, increasing until 1992 and decreasing thereafter. Similar patterns were observed by race and age group. Geographic variability in the dissemination of PSA screening was observed, yet the association between testing and incidence remained. Men in the cohort had a 4.7 percent chance of being diagnosed within three months of an initial PSA test, with the percentage falling for subsequent tests.

Conclusions: It is informative to distinguish first from later tests when assessing the effect of the diffusion of a test in a population. Taking this approach was useful in illuminating the role of PSA testing in a reversal of a long-term increase in prostate cancer incidence rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998; 48: 6–29.

    PubMed  Google Scholar 

  2. Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet 1994; 343: 251–4.

    Article  PubMed  Google Scholar 

  3. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273: 548–52.

    PubMed  Google Scholar 

  4. Merrill RM, Brawley OW. Prostate cancer incidence and mortality rates among white and black men. Epidemiology 1997; 8: 126–31.

    PubMed  Google Scholar 

  5. Merrill RM, Potosky AL, Feuer EJ. Changing trends in U.S. prostate cancer incidence rates. J Natl Cancer Inst 1996; 88: 1683–5.

    PubMed  Google Scholar 

  6. Polednak AP. Trends in prostate carcinoma incidence in Connecticut (1988-1994) by age and race. Cancer 1997; 79: 99–103.

    Article  PubMed  Google Scholar 

  7. Schwartz KL, Severson RK, Gurney JG, Montie JE. Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994. Cancer 1996; 78: 1260–6.

    PubMed  Google Scholar 

  8. Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DT, Dibble RL. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence-data from the Utah Cancer Registry. Cancer 1996; 77: 1342–8.

    PubMed  Google Scholar 

  9. Gilliland FD, Welsh DJ, Hoffman RM, Key CR. Rapid rise and subsequent decline in prostate cancer incidence rates for New Mexico, 1989-1993. Cancer Epidemiol Biomarkers Prev 1995; 4: 797–800.

    PubMed  Google Scholar 

  10. Adami HO, Baron JA, Rothman KJ. Ethics of a prostate cancer screening trial. Lancet 1994; 343: 958–60.

    Article  PubMed  Google Scholar 

  11. Woolf SH. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence [see comments]. N Engl J Med 1995; 333: 1401–5.

    Article  PubMed  Google Scholar 

  12. Denis LJ. Prostate cancer screening and prevention: ``realities and hope''. Urology 1995; 46(A): 56–61.

    Article  PubMed  Google Scholar 

  13. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993; 119: 914–23.

    PubMed  Google Scholar 

  14. Chodak GW. Screening for prostate cancer. JAMA 1994; 272: 813–4.

    PubMed  Google Scholar 

  15. Collins MN, Barry MJ. Controversies in prostate cancer screening-analogies to the early lung cancer screening debate. JAMA 1996; 276: 1976–9.

    PubMed  Google Scholar 

  16. Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG. Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians [see comments]. Ann Intern Med 1997; 126: 468–79.

    PubMed  Google Scholar 

  17. Coley CM, Barry MJ, Mulley AG. Screening for prostate cancer. Ann Intern Med 1997; 126: 480–4.

    PubMed  Google Scholar 

  18. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349: 906–10.

    Article  PubMed  Google Scholar 

  19. Fleming C, Wasson J, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993; 269: 2650–8.

    PubMed  Google Scholar 

  20. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AM, Wennberg JE, Lu-Yao GL. A structured literature review of treatment for localized prostate cancer. Arch Fam Med 1993; 2: 487–93.

    Article  PubMed  Google Scholar 

  21. Optenberg SA, Thompson IM. Economics of screening for carcinoma of the prostate. Urol Clin North Am 1990; 17: 719–37.

    PubMed  Google Scholar 

  22. Gann PH. Interpreting recent trends in prostate cancer incidence and mortality (editorial). Epidemiology 1997; 8: 117–20.

    PubMed  Google Scholar 

  23. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996; 276: 1309–15.

    PubMed  Google Scholar 

  24. Brawer MK, Chetner MP, Beatie J, Buncher DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147: 841–5.

    PubMed  Google Scholar 

  25. Brawer MK, Beatie J, Wener MH, Vessella RL, Preston SD, Lange PH. Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol 1993; 150: 106–9.

    PubMed  Google Scholar 

  26. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215–20.

    PubMed  Google Scholar 

  27. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289–94.

    PubMed  Google Scholar 

  28. Kosary CL, Ries LAG, Miller BA et al., eds. SEER Cancer Statistics Review, 1973-1992. Bethesda: National Cancer Institute; 1995.

    Google Scholar 

  29. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993; 31: 732–48.

    PubMed  Google Scholar 

  30. SAS Institute I. SAS User's Guide: Statistics. 5th ed. Cary, N.C. SAS Institute, Inc. 1985.

    Google Scholar 

  31. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute [see comments]. J Urol 1994; 152: 1905–9.

    PubMed  Google Scholar 

  32. Waterbor JW, Bueschen AJ. Prostate cancer screening (United States). Cancer Causes Control 1995; 6: 267–74.

    PubMed  Google Scholar 

  33. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer: A decision analytic view. JAMA 1994; 272: 773–80.

    PubMed  Google Scholar 

  34. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948–54.

    PubMed  Google Scholar 

  35. Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67: 2949–58.

    PubMed  Google Scholar 

  36. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156–61.

    PubMed  Google Scholar 

  37. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, Emond J. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992; 147: 846–52.

    PubMed  Google Scholar 

  38. Labrie F, Candas B, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996; 47: 212–7.

    Article  PubMed  Google Scholar 

  39. Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 1993; 42: 365–74.

    Article  PubMed  Google Scholar 

  40. DiGuiseppi C, Atkin D, and Woolf SH, eds. Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore: Williams & Wilkins, 1996.

    Google Scholar 

  41. Moon TD, Brawer MK, Wilt TJ. Prostate Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. PIVOT Planning Committee. J Natl Cancer Inst Monogr 1995; 19: 69–71.

    PubMed  Google Scholar 

  42. Schroder FH, Damhuis RAM, Kirkels WJ, de Koning HJ, Kranse R, Nus HGT, Bluenberg BG. European randomized study of screening for prostate cancer-the Rotterdam pilot studies. Int J Cancer 1996; 65: 145–51.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Legler, J.M., Feuer, E.J., Potosky, A.L. et al. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence declinein the United States. Cancer Causes Control 9, 519–527 (1998). https://doi.org/10.1023/A:1008805718310

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008805718310

Navigation